DexCom, Inc. (DXCM)
NASDAQ: DXCM · Real-Time Price · USD
58.42
-1.31 (-2.19%)
At close: Nov 20, 2025, 4:00 PM EST
58.78
+0.36 (0.62%)
After-hours: Nov 20, 2025, 7:47 PM EST
DexCom Revenue
DexCom had revenue of $1.21B in the quarter ending September 30, 2025, with 21.64% growth. This brings the company's revenue in the last twelve months to $4.52B, up 14.21% year-over-year. In the year 2024, DexCom had annual revenue of $4.03B with 11.34% growth.
Revenue (ttm)
$4.52B
Revenue Growth
+14.21%
P/S Ratio
5.06
Revenue / Employee
$438,437
Employees
10,300
Market Cap
22.78B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.03B | 410.70M | 11.34% |
| Dec 31, 2023 | 3.62B | 712.50M | 24.49% |
| Dec 31, 2022 | 2.91B | 461.30M | 18.84% |
| Dec 31, 2021 | 2.45B | 521.80M | 27.08% |
| Dec 31, 2020 | 1.93B | 450.70M | 30.54% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
DXCM News
- 14 hours ago - Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch on Dec. 1 in the United States - Business Wire
- 1 day ago - Dexcom partners with Disabled American Veterans as part of new strategic initiative - GlobeNewsWire
- 1 day ago - Dexcom Smart Basal Receives FDA Clearance Becoming the First and Only CGM-integrated Basal Insulin Dosing Optimizer for Type 2 Diabetes - Business Wire
- 3 days ago - These stocks have been hit hard in 2025 but could surge by as much as 57% from here - Market Watch
- 6 days ago - DEXCOM, INC. (NASDAQ: DXCM) INVESTOR ALERT Investors With Large Losses in DexCom, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights - GlobeNewsWire
- 6 days ago - Dexcom Reveals Global Diabetes Advocates: New Voices for Diabetes Awareness This World Diabetes Day - Business Wire
- 9 days ago - Shareholders who lost money in shares of DexCom, Inc. (NASDAQ: DXCM) Should Contact Wolf Haldenstein Immediately - PRNewsWire
- 10 days ago - DXCM STOCK NOTICE: DexCom, Inc. Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 26 Deadline - Newsfile Corp